Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis

Table 1 Relationship between neuron-glial antigen 2 expression and clinicopathological characteristics of hepatocellular carcinoma patients

Characteristic	n	NG2		χ2	P value
		High	Low
Hepatocellular carcinoma	132	84	48		< 0.0001
Non-tumor liver	96	27	69
Total cases	132	84	48
Age (yr)
≥ 50	62	40	22	0.039	0.843
< 50	70	44	26
Sex
Male	106	69	37	0.494	0.482
Female	26	15	11
Tumor size
≥ 5 cm	90	56	34	0.244	0.621
< 5 cm	42	28	14
TNM stage
I, II	52	25	27	8.976	0.002
III, IV	80	59	21
Tumor differentiation
Well	33	15	18	9.436	0.008
Moderate	52	32	20
Poor	47	37	10
Serum AFP
≥ 200 ng/dL	42	30	12	1.616	0.203
< 200 ng/dL	90	54	36
Recurrence
Yes	65	48	17	5.769	0.016
No	67	36	31
Invasion
Yes	70	51	19	5.476	0.019
No	62	33	29
Tumor number
Multiple	31	19	12	0.096	0.756
Single	101	65	36
Tumor capsule
Yes	58	33	25	2.031	0.154
No	74	51	23

AFP: Alpha fetoprotein; NG2: Neuron-glia antigen 2; HCC: Hepatocellular carcinoma; TNM stage: Tumor node metastasis stage.